Drugs, Patents and Policy
A Contextual Study of Hong Kong

Author:

A comprehensive review of Hong Kong's pharmaceutical patent law that will influence debate and inform public policy.

Language: English
Cover of the book Drugs, Patents and Policy

Subject for Drugs, Patents and Policy

Approximative price 31.58 €

In Print (Delivery period: 14 days).

Add to cartAdd to cart
Drugs, Patents and Policy
Publication date:
Support: Print on demand

Approximative price 120.27 €

In Print (Delivery period: 14 days).

Add to cartAdd to cart
Drugs, Patents and Policy
Publication date:
234 p. · 15.7x23.5 cm · Hardback
In pharmaceutical patent law, the problem of lack of policy direction and inappropriate legal framework is widespread - particularly among jurisdictions with little to no pharmaceutical research or manufacturing. This book aims to inform public policy and influence debate through a comprehensive review of Hong Kong's pharmaceutical patent law. By demonstrating the need for a holistic review of pharmaceutical patent laws and evaluating Hong Kong's system in light of health policy, economic and social factors, Bryan Mercurio recommends changes to the legal framework and constructs a more efficient and effective system for Hong Kong. He thoroughly evaluates the international framework and best practice models to offer a global perspective to each issue before providing local context in the analysis. While the focus of the book is Hong Kong, the analysis on pharmaceutical patent law and policy extends to other jurisdictions facing issues on reforming their national system.
1. Introduction; 2. The contextual framework of Hong Kong's pharmaceutical patent laws and policy; 3. Standards of patentability; 4. Extension of patent terms for pharmaceutical products; 5. Exceptions to exclusive rights; 6. Test data exclusivity; 7. Patent linkage; 8. Conclusion.
Bryan Mercurio is Professor of Law, Associate Dean (Research) and Vice Chancellor's Outstanding Fellow of the Faculty of Law at The Chinese University of Hong Kong. He is a leading expert in the intersection between trade law and intellectual property rights.